(Sharecast News) - Vanda Pharmaceuticals shares rocketed on Wednesday after the US Food and Drug Administration approved its motion sickness drug.
The approval - for Nereus (tradipitant) - marks the first new pharmacologic treatment in motion sickness in more than four decades. Vanda said it represents "a significant advancement in the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE